1. |
A consensus statement on the management of hypertrophic cardiomyopathy has been developed and published |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 442,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
2. |
Fondaparinux a step up for VTE prophylaxis |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 442,
2003,
Page 3-4
&NA;,
Preview
|
|
摘要:
The risk of developing postoperative venous thromboembolism (VTE) is very high for patients undergoing hip fracture or other major orthopaedic surgery. Deep vein thrombosis (DVT) or pulmonary embolism (PE) can result, and the latter is often fatal. In addition, subsequent complications, including recurrences and ongoing post-thrombotic syndrome (PTS) can prove costly and resource intensive. Low molecular weight heparins, such as enoxaparin sodium, are widely used for routine prophylaxis among these patients. However, recently, the novel pentasaccharide fondaparinux sodium [Arixtra] has been approved for VTE prophylaxis among patients undergoing orthopaedic surgery, and has proven to be more effective than enoxaparin in preventing VTE after hip fracture surgery. The number of patients undergoing hip fracture surgery is rising, in part due to the ageing population worldwide. Thus, assessment of the clinical and economic effects of introducing fondaparinux into clinical practice is of significant value to physicians and healthcare providers. Several studies examining these issues were presented at a large poster session at the 6th Annual European Conference of the International Society of Pharmacoeconomics and Outcomes Research [ISPOR, Nov 2003; Barcelona, Spain].
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
3. |
Medication pricing, access requires pharma industry defence |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 442,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
4. |
Valdecoxib reduces resource use, costs in RA |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 442,
2003,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
5. |
The Severity of Dyspepsia Assessment (SODA) is a"new and effective evaluative instrument"for measuring the"clinically relevant"outcomes of dyspepsia, |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 442,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
6. |
Gatifloxacin-containing regimens cost saving in CAP |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 442,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
7. |
CAM use becoming more diverse in prostate cancer |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 442,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
8. |
Scalding drug costs for Canadian burn unit |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 442,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
9. |
Paediatric antibacterial use on the decline in the US |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 442,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
10. |
QOL effects of C-reactive protein levels in diabetes |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 442,
2003,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|